When obsessive-compulsive disorder (OCD), a recurring topic is whether psychoanalysis or related brief psychotherapies help and answering that was the goal a study performed by researchers of the University of Torino in the current issue of Psychotherapy and Psychosomatics.
Until now no studies have investigated the benefits of adding brief dynamic therapy (BDT) to medication in obsessive-compulsive disorder, while a number of recent investigations have demonstrated the efficacy of supplemental BDT among patients with major depressive disorders (MDD).
The objective of this study was to explore the efficacy of BDT combined with pharmacotherapy in comparison with pharmacotherapy alone in the treatment of OCD with concurrent MDD. A 12-month randomized clinical trial compared a standard selective serotonin reuptake inhibitor treatment with (n = 27) or without (n = 30) supplemental BDT in patients with OCD and concurrent MDD. Supplemental BDT was added during the first 16-week trial; all patients continued to be treated with only pharmacotherapy in the following continuation phase.
The primary efficacy assessments were the Yale-Brown Obsessive Compulsive Scale and the 17-item Hamilton Rating Scale for Depression; the secondary efficacy measures included the Clinical Global Impression Scale and the Global Assessment of Functioning. The data analysis was conducted on the ‘intent-to-treat (ITT) efficacy patient sample’. Fifty patients completed the study. No difference between the 2 treatment groups was found at any point by any assessment method in the ITT study sample.
Supplemental BDT in the treatment of patients with OCD with concurrent MDD who are receiving effective medication has no significant clinical effect on both obsessive and depressive symptoms.
Citation: G. Maina, G. Rosso, S. Rigardetto, S. Chiadò Piat, F. Bogetto, 'No Effect of Adding Brief Dynamic Therapy to Pharmacotherapy in the Treatment of Obsessive-Compulsive Disorder with Concurrent Major Depression', Psychother Psychosom 2010;79:295-302 DOI: 10.1159/000318296
- Psychotherapists Say They Can Fix The Problems Caused By Psychiatric Drugs
- Shire Reports Positive Phase II Results For Investigative Use Of Vyvanse® (lisdexamfetamine Dimesylate) Capsules, (CII)
- Brain Stimulation Device For Treatment Of Obsessive-Compulsive Disorder Approved In Europe
- Deep Brain Stimulation For OCD Releases Dopamine In The Brain
- Valdoxan(R), The First Melatonergic Antidepressant, Receives EU CHMP Positive Opinion For Major Depressive Disorder